Your browser doesn't support javascript.
loading
A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study).
Brivio, Erica; Locatelli, Franco; Lopez-Yurda, Marta; Malone, Andrea; Díaz-de-Heredia, Cristina; Bielorai, Bella; Rossig, Claudia; van der Velden, Vincent H J; Ammerlaan, Anneke C J; Thano, Adriana; van der Sluis, Inge M; den Boer, Monique L; Chen, Ying; Sleight, Barbara; Brethon, Benoit; Nysom, Karsten; Sramkova, Lucie; Øra, Ingrid; Vinti, Luciana; Chen-Santel, Christiane; Zwaan, Christian Michel.
Afiliação
  • Brivio E; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Locatelli F; Department of Pediatric Oncology, Erasmus Medical Center (Erasmus MC) Sophia Children's Hospital, Rotterdam, The Netherlands.
  • Lopez-Yurda M; Department of Pediatric Hematology/Oncology and Cell and Gene Therapy, Ospedale Pediatrico Bambino Gesù, Sapienza University of Rome, Rome, Italy.
  • Malone A; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Díaz-de-Heredia C; Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Bielorai B; Children's Health Ireland at Crumlin, Dublin, Ireland.
  • Rossig C; Department of Pediatric Hematology and Oncology, University Hospital Vall d'Hebron, Barcelona, Spain.
  • van der Velden VHJ; Department of Pediatric Hematology-Oncology, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat-Gan, Israel.
  • Ammerlaan ACJ; Department of Pediatric Hematology and Oncology, University Children's Hospital Münster, Germany.
  • Thano A; Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • van der Sluis IM; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • den Boer ML; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Chen Y; Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Sleight B; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Brethon B; Department of Pediatric Oncology, Erasmus Medical Center (Erasmus MC) Sophia Children's Hospital, Rotterdam, The Netherlands.
  • Nysom K; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Sramkova L; Department of Pediatric Oncology, Erasmus Medical Center (Erasmus MC) Sophia Children's Hospital, Rotterdam, The Netherlands.
  • Øra I; The Oncode Institute, Utrecht, The Netherlands.
  • Vinti L; Pfizer Global Product Development, San Diego, CA.
  • Chen-Santel C; Pfizer Inc, Groton, CT.
  • Zwaan CM; Department of Pediatric Hematology, Hôpital Robert-Debré, Assistance Publique-Hôpitaux de Paris, Paris, France.
Blood ; 137(12): 1582-1590, 2021 03 25.
Article em En | MEDLINE | ID: mdl-33067614
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras / Antineoplásicos Imunológicos / Inotuzumab Ozogamicina Tipo de estudo: Clinical_trials / Guideline Limite: Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Blood Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Holanda
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras / Antineoplásicos Imunológicos / Inotuzumab Ozogamicina Tipo de estudo: Clinical_trials / Guideline Limite: Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Blood Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Holanda